Evaluation of the anticancer action of a permanently charged tamoxifen derivative, tamoxifen methiodide: An MRI study

International Journal of Pharmaceutics

Volumn 153, Issue 2, 1997, Pages 147-157

  Brewster, Marcus E ^a,b,c   Paran, Yael ^b   Rushkin, Edna ^b   Biegen, Anat ^c   Pop, Emil ^a   Degani, Hadassa ^b  

^a Pharmos Corporation   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c PHARMOS LTD   (Israel)

Author keywords

Breast cancer; Magnetic resonance imaging (MRI); MCF 7 cell culture; Tamoxifen; Tamoxifen methiodide (TMI)

Indexed keywords

ESTRADIOL; PLACEBO; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TAMOXIFEN METHIODIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER REGRESSION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030842389     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)04921-1     Document Type: Article

References (17)

1. Berthois, Y., Katzenellenbogen, J., Katzenellenbogen, B., 1986. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. USA 83, 2496-2500.
2. Biegon, A., Brewster, M., Degani, H., Pop, E., Somjen, D., Kaye, A., 1996. A permanently charged tamoxifen derivative displays anti-cancer activity and improved tissue selectivity in rodents. Cancer Res. 56, 4328-4331.
3. Bottega, R., Epand, R.M., 1992. Inhibition of protein kinase C by cationic amphiphiles. Biochemistry 31, 9025-9030.
4. Buckley, M., Goa, K., 1989. Tamoxifen, a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37, 451-490.
5. Bush, T., Helzlsouer, K., 1993. Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial. Epidemiol. Rev. 15, 233-243.
6. Cathcart, C., Jones, S., Pumroy, C., Peters, G., Knox, S., Cheek, J., 1993. Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 27, 277-281.
7. Costa, A., 1993. Breast cancer chemoprevention. Eur. J. Cancer 29A, 589-592.
8. Degani, H., Furman, E., Fields, S., 1994. Magnetic resonance imaging and spectroscopy of MCF-7 human breast cancer: pathophysiology and monitoring of treatment. Clin. Chim. Acta 228, 19-33.
9. DeJordy, J., Bendel, P., Horwitz, A., Salomon, Y., Degani, H., 1992. Correlation of MR imaging and histologic findings in mouse melanoma. JMRI 2, 695-700.
10. Early Breast Cancer Trialists' Collaborative Group, 1992. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339, 1-15 and 71-85.
11. El-Ashry, D., Lippman, M., 1994. Molecular biology of breast carcinoma. World J. Surg. 18, 12-20.
12. Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N., Wolmark, N., Wickerham, D., Fisher, E., Margolese, R., Robidoux, A., Shibata, H., Terz, J., Paterson, A., Feldman, M., Farrar, W., Evans, J., Lickley, H., Ketner., M., 1989. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N. Engl. J. Med. 320, 479-494.
13. Folkman, J., 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
14. Folkman, J., 1990. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4-6.
15. Fornander, T., Cedermark, B., Mattsson, A., Skoog, L., Askergren, J., Rutqvist, L., Glas, U., Silfverswäed, C., Somell, A., Wilking, N. and Hjalmar. M., 1989. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet I, 117-119.
16. Friedman, Z., Minz, E., Selinger, Z., 1995. Effects of structural modifications of tamoxifen on phospholipase C and phosphoinositide kinase activities. Isr. J. Med. Sci. 31, 758.
17. Furman, E., Margalit, R., Bendel, P., Horwitz, A., Degani, H., 1991. In vivo studies by magnetic resonance imaging and spectroscopy of the response to tamoxifen of MCF-7 human breast cancer implanted in nude mice. Cancer Commun. 3, 287-297.